Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies, have revolutionized the therapy landscape of cancer immunotherapy. However, poor clinical response to ICIs and drug resistance are the main challenges for ICIs immunotherapy. TGF-β produced in the TME was found...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Zhen-Hua, Li, Na, Gao, Zhang-Zhao, Chen, Gang, Nie, Lei, Zhou, Ya-Qiong, Jiang, Mei-Zhu, Chen, Yao, Chen, Juan, Mei, Xiao-Fen, Hu, Feng, Wang, Hai-Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562016/
https://www.ncbi.nlm.nih.gov/pubmed/36230887
http://dx.doi.org/10.3390/cancers14194964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562016/
https://www.ncbi.nlm.nih.gov/pubmed/36230887
http://dx.doi.org/10.3390/cancers14194964

Ejemplares similares